RAY-VASC Thesis: A Longitudinal N-of-1 Observational Research Program for Residual Adaptive Capacity, Neuropathic Pathway Repair and Remapping, and Personalized Neurotrophic Optimization in Progressive Supranuclear Palsy with Vascular Dementia, Post-Stroke Sequelae, and COPD

RAY-VASC is a longitudinal N-of-1 and small-series research architecture designed to test whether residual functional capacity in complex neurovascular phenotypes can be characterized and tracked under a structured, multidomain measurement program. The architecture integrates baseline case characterization, evidence-graded candidate mapping, case-specific safety and eligibility filtering, high-frequency subjective and objective measurement, confounder annotation, preregistered analysis, and transparent response-policy documentation. The thesis formalizes the Neuropathic Repair-Remap Hypothesis, the Regenerative Loop, the Three-Phase Plasticity Architecture, the Algorithmic Personalization Predictive Response Engine (APPRE), and the responseome as a longitudinal representation of domain-level change. It distinguishes the Layer 1 candidate universe from the Layer 2 participant-specific implementation filter so that biological plausibility is not confused with eligibility, safety, or causal interpretation. RAY-001 is presented as the originating and methodological stress-test case rather than as proof of efficacy. The case combines progressive supranuclear palsy, vascular cognitive impairment and dementia, post-stroke sequelae, severe sleep disruption, respiratory disease, medication interactions, renal variability, falls risk, dysphagia, and caregiver constraints. These features are used to derive an auditable measurement and safety architecture capable of supporting future replication, small-series expansion, and separately governed research on plasticity-window interventions. The thesis synthesizes the four published RAY-VASC papers and defines the planned Papers 5–7 research pathway. It is hypothesis-generating and does not establish clinical efficacy, disease modification, neurological repair, reversal, recovery, cure, or guaranteed benefit. Controlled-substance content is limited to published evidence and lawful, clinician-governed, ethics-approved research contexts.